AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Core Insights - AIM ImmunoTech Inc. is making significant progress in its clinical development programs, particularly in the high-value pancreatic cancer sector, highlighting the potential for collaboration with big pharmaceutical companies and commercialization opportunities [1][2] Financial Highlights - As of September 30, 2024, AIM reported cash, cash equivalents, and marketable securities totaling $7.2 million [4] - Research and development expenses for Q3 2024 were $1.4 million, a decrease from $2.7 million in Q3 2023 [4] - General and administrative expenses were $3.1 million for Q3 2024, down from $5.4 million in the same period of 2023 [4] - The net loss from operations for Q3 2024 was $3.7 million, or $0.06 per share, compared to a net loss of $7.8 million, or $0.16 per share, for Q3 2023 [4] Conference Call and Webcast - The company will host a conference call and webcast on November 15, 2024, at 8:30 AM ET to discuss its Q3 2024 operational and financial results [6][7]